Please check your internet connection and try again.
# Calcium Acetate
## Overview
Calcium acetate is a phosphate binder used to control hyperphosphatemia in patients with chronic kidney disease (CKD). It works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption.
## Primary Indications
* Treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD).
## Adult Dosing
* **Initial Dose:** 1330 mg (667 mg elemental calcium) administered orally with meals.
* **Titration:** Doses should be titrated based on serum phosphate levels. Dosing is highly individualized.
* **Typical Maintenance Dose:** May range from 1330 mg to 3990 mg (667 mg to 1998 mg elemental calcium) per day, divided with meals.
* **Maximum Dose:** Generally not to exceed 3990 mg (1998 mg elemental calcium) per day, though higher doses may be used under specific clinical guidance to achieve target phosphate levels.
## Pediatric Dosing
* Data on pediatric dosing is limited. Refer to institutional protocols or specialized pediatric resources. Generally, lower doses are used, and titration is guided by serum phosphate levels and calcium levels.
## Dose Adjustments
* **Renal Impairment:** Patients with CKD require careful monitoring. Dose adjustments are primarily driven by serum phosphate and calcium levels.
* **Hypercalcemia:** If hypercalcemia occurs, the dose of calcium acetate should be reduced or discontinued.
## Contraindications
* Hypercalcemia.
* Hypersensitivity to calcium acetate or any component of the formulation.
* T normal anion gap metabolic acidosis.
## Adverse Effects
* **Common:** Hypercalcemia, nausea, vomiting, constipation, diarrhea, dyspepsia, abdominal pain.
* **Serious:** Severe hypercalcemia (symptoms include confusion, lethargy, arrhythmias, constipation, bone pain, polyuria, polydipsia), vascular calcification.
## Key Drug Interactions
* **Tetracyclines and Quinolones:** Calcium acetate can decrease the absorption of these antibiotics. Administer these agents at least 2 hours before or 3 hours after calcium acetate.
* **Thyroid Hormones:** Calcium acetate can reduce the absorption of levothyroxine. Separate administration by at least 4 hours.
* **Digoxin:** Hypercalcemia may increase the risk of digoxin toxicity.
* **Vitamin D Analogues:** Concurrent use may increase the risk of hypercalcemia.
## Monitoring
* **Serum Phosphate:** Monitor regularly, typically within weeks of initiation or dose adjustment, and then periodically as clinically indicated. Target levels are often < 5.5 mg/dL.
* **Serum Calcium:** Monitor regularly, especially at the initiation of therapy, with dose changes, and periodically thereafter. Target levels are generally below the upper limit of normal (e.g., < 10.5 mg/dL or < 11 mg/dL, depending on guidelines). Correct for serum albumin if necessary.
* **Alkaline Phosphatase:** May be monitored to assess bone metabolism.
* **Electrolytes:** Monitor periodically.
## Clinical Pearls
* Calcium acetate should be administered with meals to effectively bind dietary phosphate.
* Careful monitoring of both serum calcium and phosphate is crucial to avoid hypercalcemia and manage hyperphosphatemia effectively.
* The goal is to achieve serum phosphate levels within target ranges while maintaining serum calcium levels at the lower end of the normal range or slightly below, to minimize the risk of hypercalcemia and vascular calcification.
* Patients should be advised to report symptoms of hypercalcemia.
***
*Disclaimer: This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions. Dosing and management may vary based on individual patient factors and local protocols.*
